Conceptus, Inc. (NASDAQ:CPTS)

CAPS Rating: 5 out of 5

The Company develops, manufactures and markets the Essure(r) permanent birth control system, an innovative and proprietary medical device for women.

Results 1 - 13 of 13

Recs

0
Member Avatar scrubs62074 (88.38) Submitted: 2/8/2013 8:49:24 AM : Outperform Start Price: $22.64 CPTS Score: +6.77

High volume breakout on 2/7/13

Recs

0
Member Avatar emeraldvale (< 20) Submitted: 8/30/2011 9:33:12 AM : Outperform Start Price: $10.72 CPTS Score: +126.53

ms screen

Recs

0
Member Avatar icrazy (22.14) Submitted: 6/7/2011 1:18:47 PM : Outperform Start Price: $13.17 CPTS Score: +83.72

Call me crazy, but it looks as if this one is gaining some momentum upward.

Recs

0
Member Avatar valuefocusgroup (< 20) Submitted: 4/5/2011 9:49:22 AM : Outperform Start Price: $14.63 CPTS Score: +64.18

Price/earnings of 5.63, market cap of 454.36 million, Debt/equity of 0.53, Return on Invested Capital (TTM) of 41.08, based in California, United States, focus on minimally invasive devices for reproductive medical applications.

Recs

0
Member Avatar colonel79 (< 20) Submitted: 1/11/2010 2:26:43 PM : Outperform Start Price: $18.08 CPTS Score: -0.39

This stock has all the forces pushing it to success:
-Little to no debt
-Strong growth
-Recent positive earnings
-Liberal governments that will reimburse them for helping women prevent unwanted children
-Economic forces that will limit the number of children people want to have
-Other procedures available for women to prevent unwanted pregnancies involve chemicals, pills, are surgery and this is cheaper than the alternatives
-Company has patents
-Proven need for these products
-P/E is currently high, but net income to increase 128% in 2010.

Slam dunk and I will probably by this with my own money.

Recs

0
Member Avatar freebirdrenee (< 20) Submitted: 10/13/2008 4:38:08 AM : Outperform Start Price: $12.48 CPTS Score: +34.68

For a woman who is certain they do not want any more children this is the way to go! Insurance Companies are already on board and it is being used world wide. Medicade is also paying for this procedure and the government is always the last to sign on to pay for a procedure. This is an in-office procedure does not require any time off to recover therefore less time off from work. Additionally this is great for the women who have small children at home because you don't have any restrictions after the procedure.

Recs

0
Member Avatar dmoromisato (< 20) Submitted: 6/3/2008 4:20:04 PM : Outperform Start Price: $18.01 CPTS Score: +24.10

New standard in permanent birth control, if the Buffet Foundation can recognize, it will be standard in the world.

Recs

0
Member Avatar Waynoooo (70.68) Submitted: 1/14/2008 7:37:08 PM : Outperform Start Price: $16.01 CPTS Score: +46.92

Marketing a radical form of birth control, making choice easier for all women

Recs

0
Member Avatar brentan0 (63.36) Submitted: 10/22/2007 11:37:56 AM : Outperform Start Price: $19.40 CPTS Score: +21.99

Looks undervalued, with next years Q1 earnings estimated 72% above this year's.

Recs

0
Member Avatar rxrobert1 (57.53) Submitted: 3/29/2007 10:17:18 AM : Outperform Start Price: $19.55 CPTS Score: +12.36

only manufacturer of current product

Recs

0
Member Avatar skillcat (< 20) Submitted: 12/9/2006 1:45:32 PM : Outperform Start Price: $21.88 CPTS Score: -6.04

proven needed product.

Recs

1
Member Avatar wbce1866 (< 20) Submitted: 9/19/2006 4:07:15 AM : Outperform Start Price: $17.59 CPTS Score: +18.13

Women guide family healthcare. They call the shots and this is what they'll want.

Recs

2
Member Avatar 2subarus (99.29) Submitted: 8/23/2006 10:11:55 PM : Outperform Start Price: $16.56 CPTS Score: +25.92

Conceptus Ensure is going to revolutionize permanent birth control and replace tubal ligations. It is simple, done in an office, rather than an operating room. At this time there is no competition. As more doctors get trained in this procedure, and patients get informed, and every quarter their earnings grow, this stock is going to shoot to the stars.

Results 1 - 13 of 13

Featured Broker Partners


Advertisement